Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Rodman & Renshaw Annual Investment Conference 2015
11 slides from Mayne Pharma's conference presentation, Sep 9, 2015
Slide 1: Mayne Pharma Group Limited Company Presentation
Mayne Pharma Group Limited Company Presentation Rodman & Renshaw Annual Investment Conference September 9th, 2015 Stefan Cross, President, Mayne Pharma USA
Slide 2: Mayne Pharma is a diverse global pharma company
Mayne Pharma is a diverse global pharma company By geography ● Mayne Pharma is an Australian-listed specialty pharmaceutical company, headquartered in Adelaide 5% USA 17% ● Develops and manufactures generic and proprietary Australia A$141m pharmaceuticals which are distributed globally either Rest o
Slide 3: Company history
Company history 1845 Leading Australian healthcare company with over 150 years of history 1970s Development of enteric coated erythromycin (Eryc™) FDA approval and first US sales of Eryc™ by Warner Lambert (Warner Chilcott) FH Faulding & Co 1980s Salisbury site acquired in 1983 Development o
Slide 4: Mayne Pharma's international footprint
Mayne Pharma’s international footprint Commercial office Raleigh, North Carolina Product development and manufacturing facility space. FDA approved. US$6514.6 hectare facility at Greenville, North Carolina has 99,200ft2 of manufacturing m strategic investment in new greenfield oral dose commercial m
Slide 5: Mayne Pharma's business structure
Mayne Pharma’s business structure United States Rest of world US Generic Products Metrics US Specialty Brands Mayne Pharma (GPD) Contract Services (SBD) International (MPI) (MCS) Develops, manufactures, Responsible for the Provides contract Develops, manufactures, Overview markets and distri
Slide 6: FY15 operational and financial highlights
FY15 operational and financial highlights ● Transformational US$50m Doryx™ acquisition completed which has diversified and transformed the earnings profile ● US Specialty Brands Division created with a 60+ person sales team to market specialty brands in the US ● Expanded marketed product portfolio a
Slide 7: Doryx - the "game changer" for Mayne Pharma
Doryx™ - the “game changer” for Mayne Pharma 1 Transformed earnings base following Doryx acquisition 2 Attractive market fundamentals in US dermatology space 3 Optimize Doryx sales through: ● Mayne Pharma’s sales force, which will be focused and dedicated to marketing Doryx ● Further product pricing
Slide 8: Development pipeline expected to drive long-term sustainable growth
Development pipeline expected to drive long-term sustainable growth ● Team of 60+ professionals in R&D with particular US Pipeline statistics – IMS market size (US$bn)1 August 2015 expertise in formulating complex oral dose forms including - highly potent compounds 8.0 - schedule II-V controlled sub
Slide 9: 5 pillars of our corporate strategy
5 pillars of our corporate strategy 1. US retail generics 4. Strategic acquisitions, 3. R&D maximization maximization licensing and partnerships 2. Establish a US branded 5. Optimize and grow US specialty franchise contract services 9
Slide 10: Outlook
Outlook US Specialty ● New segment will capture full year contribution from Doryx Brands Division ● Recent launch of 50mg Doryx tablet is expected to grow the franchise (SBD) ● Expected monthly EBITDA contribution of US$2.7m on average in FY16 from US Doryx franchise US Generic ● US generic market g
Slide 11: A specialty pharmaceutical company with an increasingly diversified portfolio
A specialty pharmaceutical company with an increasingly diversified portfolio of products, technologies and footprint 11
Mayne Pharma Group — Rodman & Renshaw Annual Investment Conference 2015 on 6ix